Mylotarg
PHONETIC PRONUNCIATION: Mylotarg
Description
Mylotarg, also known as gemtuzumab ozogamicin, is a medication used in the treatment of certain types of acute myeloid leukemia. It is a chemotherapy drug that works by binding to receptors on leukemia cells and delivering a toxic substance that kills the cells. Uses: Mylotarg is used to treat patients with acute myeloid leukemia (AML) who have previously been treated with chemotherapy but whose cancer has returned or has not gone into remission. It can also be used in combination with other chemotherapy drugs in newly diagnosed patients with a specific genetic mutation. Dosage: The dosage of Mylotarg is based on the patient's weight and overall health. It is typically given as an intravenous infusion over a period of 2 hours. The recommended dosage is 3 milligrams per square meter of body surface area, given every 4 weeks for up to 6 cycles. Demographic: Mylotarg is approved for use in adults with AML. It is not recommended for use in pediatric patients. Side Effects: The most common side effects of Mylotarg include fever, chills, nausea, vomiting, constipation, diarrhea, fatigue, and shortness of breath. More serious side effects can occur, including an increased risk of infection, bleeding, and liver damage. Interactions: Mylotarg may interact with other drugs or supplements a patient is taking. Patients should inform their healthcare provider of all medications, vitamins, and supplements they are taking before starting Mylotarg. Generic Options: There are currently no generic versions of Mylotarg available on the market. In conclusion, Mylotarg is a chemotherapy drug used in the treatment of certain types of acute myeloid leukemia. It is given as an intravenous infusion and can have side effects that range from mild to serious. Patients should inform their healthcare provider of all medications, vitamins, and supplements they are taking before starting Mylotarg. There are currently no generic versions available on the market.
Faq for Mylotarg
Mylotarg (gemtuzumab ozogamicin) is used to treat certain types of acute myeloid leukemia (AML) in adults and children above one month.
Mylotarg is an antibody-drug conjugate that contains an antibody targeting CD33, a protein found on leukemic cells. The drug binds to CD33 and releases a toxic substance, calicheamicin, which enters the cancer cells and damages their DNA, leading to cell death.
The most common side effects of Mylotarg include fever, nausea, infection, headache, rash, vomiting, abdominal pain, fatigue, and bleeding. Some patients may also experience liver toxicity or severe infusion reactions.
Mylotarg is given as an intravenous (IV) infusion through a vein over approximately 2 hours. The exact dosage and schedule will be determined by your healthcare provider based on your specific condition.
The duration of Mylotarg treatment can vary depending on the response and tolerability of the patient. It is typically given once every few weeks for several cycles. Your doctor will monitor your progress and adjust the treatment plan accordingly.
It is important to inform your doctor about any pre-existing medical conditions, allergies, medications you are currently taking, and previous treatments for leukemia. Discussing potential risks, benefits, and alternatives to Mylotarg is crucial before starting the treatment.
Mylotarg carries a boxed warning about the risk of severe liver damage, including the risk of veno-occlusive disease (VOD) or hepatotoxicity. It is necessary to monitor liver function and take appropriate precautions while using this medication.
Mylotarg can harm an unborn baby, and its use should be avoided during pregnancy. It is also not recommended while breastfeeding, as it may pass into breast milk and harm the nursing infant. Discuss with your healthcare provider for specific guidance.
Certain medications, including those affecting liver enzymes or blood clotting, may interact with Mylotarg. Inform your doctor about all the medications, supplements, or herbal products you are taking to avoid potential interactions.